Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Investment Securities (2016 - 2026)

Arcus Biosciences has reported Gains from Investment Securities over the past 9 years, most recently at -$6.0 million for Q4 2024.

  • For Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$6.0 million; the TTM value through Sep 2025 reached -$6.0 million, up 62.5%, while the annual FY2024 figure was -$22.0 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2024 was -$6.0 million at Arcus Biosciences, down from -$1.0 million in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $8.0 million in Q1 2023 and troughed at -$10.0 million in Q2 2022.
  • A 5-year average of -$1.4 million and a median of -$408000.0 in 2021 define the central range for Gains from Investment Securities.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 3269.23% in 2020 and later surged 11211.11% in 2022.
  • Year by year, Gains from Investment Securities stood at -$7.0 million in 2020, then soared by 153.54% to $3.8 million in 2021, then crashed by 260.0% to -$6.0 million in 2022, then surged by 83.33% to -$1.0 million in 2023, then plummeted by 500.0% to -$6.0 million in 2024.
  • Business Quant data shows Gains from Investment Securities for RCUS at -$6.0 million in Q4 2024, -$1.0 million in Q3 2024, and -$10.0 million in Q2 2024.